Tokio Marine Asset Management Co. Ltd. raised its holdings in shares of Merck & Company, Inc. (NYSE:MRK) by 82.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 77,805 shares of the company’s stock after purchasing an additional 35,119 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Merck & were worth $4,987,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Cascade Investment Advisors Inc. increased its stake in Merck & by 15.5% during the second quarter. Cascade Investment Advisors Inc. now owns 1,727 shares of the company’s stock valued at $111,000 after purchasing an additional 232 shares during the last quarter. Vigilant Capital Management LLC increased its stake in Merck & by 16.7% during the first quarter. Vigilant Capital Management LLC now owns 1,746 shares of the company’s stock valued at $111,000 after purchasing an additional 250 shares during the last quarter. Harbour Capital Advisors LLC bought a new stake in Merck & during the first quarter valued at $127,000. Mascoma Wealth Management LLC increased its stake in Merck & by 8.2% during the second quarter. Mascoma Wealth Management LLC now owns 2,474 shares of the company’s stock valued at $159,000 after purchasing an additional 187 shares during the last quarter. Finally, Gradient Investments LLC increased its stake in Merck & by 17.5% during the second quarter. Gradient Investments LLC now owns 2,710 shares of the company’s stock valued at $174,000 after purchasing an additional 404 shares during the last quarter. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at 64.33 on Tuesday. The firm has a market cap of $175.45 billion, a P/E ratio of 34.83 and a beta of 0.80. Merck & Company, Inc. has a 12-month low of $58.29 and a 12-month high of $66.80. The company has a 50-day moving average of $64.35 and a 200 day moving average of $63.69.

Merck & (NYSE:MRK) last announced its earnings results on Friday, July 28th. The company reported $1.01 EPS for the quarter, topping the consensus estimate of $0.87 by $0.14. The company had revenue of $9.93 billion for the quarter, compared to analysts’ expectations of $9.75 billion. Merck & had a return on equity of 26.02% and a net margin of 17.14%. The business’s revenue for the quarter was up .9% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.93 earnings per share. Equities analysts predict that Merck & Company, Inc. will post $3.87 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, October 6th. Stockholders of record on Friday, September 15th were issued a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 2.92%. The ex-dividend date was Thursday, September 14th. Merck &’s payout ratio is presently 76.11%.

ILLEGAL ACTIVITY WARNING: “Tokio Marine Asset Management Co. Ltd. Acquires 35,119 Shares of Merck & Company, Inc. (MRK)” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/10/tokio-marine-asset-management-co-ltd-acquires-35119-shares-of-merck-company-inc-mrk.html.

Several analysts have weighed in on MRK shares. UBS AG boosted their target price on shares of Merck & from $70.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on shares of Merck & and gave the company a “buy” rating in a report on Saturday, July 29th. BMO Capital Markets reissued a “buy” rating and set a $74.00 price target on shares of Merck & in a report on Tuesday, June 27th. Credit Suisse Group reissued a “buy” rating on shares of Merck & in a report on Tuesday, June 13th. Finally, BidaskClub raised shares of Merck & from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have given a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $69.81.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Stock Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related stocks with our FREE daily email newsletter.